MedTrace Logo

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

NCT02462161 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-07-28

No results posted yet for this study

Summary

This pilot clinical trial will examine the effects of intranasal insulin aspart on cognition, daily function, blood and cerebral spinal fluid markers of Alzheimer's disease, and amyloid deposition in the brain. Participants will be randomly assigned to receive insulin aspart or placebo during a 12-week treatment period.

Conditions

Interventions

DRUG

Insulin aspart

Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.

DRUG

Placebo

Participants will administer placebo two times per day with an intranasal delivery device.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • General Electric

    collaborator INDUSTRY

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Suzanne Craft, PhD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-20
Primary Completion
2019-04-16
Completion
2019-04-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462161 on ClinicalTrials.gov